Leadership and governance
Experience across science, pharmaceuticals and operations.
AERASYN's board, executive team, scientific team and advisors support the development of an integrated neurotherapeutics platform.
Leadership information updated August 2026
Governance
Board of Directors
Corporate and scientific oversight for the AERASYN platform.
George Jackowski, PhD
Chairman & CSO
John DiGirolamo
Director
Fabian Monaco
Director
Company leadership
Executive Team
Leadership across corporate strategy, operations, finance and scientific communications.
Santino Bernaudo
Co-Founder & President
David Kideckel
Chief Executive Officer
Bruno Memme
Interim CFO
Arlene Piper
VP, Scientific Communications
Michael Haslam
Director of Operations
Research leadership
Scientific Team
Scientific contributors spanning chemistry, analytical science, pharmaceutical biology and behavioural research.
George Jackowski, PhD
Chairman & CSO
Prof. John Trant, PhD
Chemistry
John Hayward, PhD
Chemistry Research Associate
Prof. Luigi Mondello, PhD
Head of Analytical Chemistry
Anna Notti, PhD
Head of Organic Chemistry
Prof. Luca Santi
Head of Pharmaceutical Biology
Prof. Salvatore Cuzzocrea, PhD
Head of Behavioural Studies
Strategic guidance
Advisory Team
Pharmaceutical and capital-markets perspective supporting company strategy.
John Haslam
Sr. Pharmaceutical Advisor
James Cran
Sr. Pharmaceutical Advisor
Jason Monaco
Capital Markets Advisor
Scientific network
Academic relationships extend scientific capability.
AERASYN's scientific team is complemented by academic relationships across the company's research network.
Explore the scientific networkWork with AERASYN
Connect with company leadership.
Discuss research collaboration, technology licensing or strategic relationships.
Start a Conversation